0000896262-23-000068.txt : 20230905 0000896262-23-000068.hdr.sgml : 20230905 20230905205602 ACCESSION NUMBER: 0000896262-23-000068 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230824 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Guidroz Allyson CENTRAL INDEX KEY: 0001991938 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 231237606 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 3 1 wf-form3_169396174597780.xml FORM 3 X0206 3 2023-08-24 0 0000896262 AMEDISYS INC AMED 0001991938 Guidroz Allyson 3854 AMERICAN WAY , SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Accounting Officer Common Stock 5134 D Common Stock 1.50 I By 401(k) Plan Stock Option (Right to Buy) 95.76 2028-07-25 Common Stock 272.0 D Stock Option (Right to Buy) 132.41 2029-07-25 Common Stock 640.0 D Stock Option (Right to Buy) 214.74 2030-07-25 Common Stock 563.0 D Stock Option (Right to Buy) 264.0 2031-07-25 Common Stock 590.0 D Includes 117 performance-based restricted stock units tied to a performance metric for the 2020 fiscal year, which was certified as achieved and subject to further time-based vesting on July 25,2024; 118 time-based restricted stock units ("RSUs") that vest on July 25, 2024; 60 time-based RSUs that vest on July 25, 2025; 406 time-based RSUs that vest on each of June 1, 2024, 2025 and 2026; 647 time-based RSUs that vest on each of May 3, 2024, 2025 and 2026; and 648 time-based RSUs that vest on May 3, 2027, assuming in each case that the Reporting Person remains continuously employed by the Issuer on each such vesting date. The information in this report is based on a plan statement dated as of June 30, 2023. All 272 stock options are fully vested and immediately exercisable. All 640 stock options are fully vested and immediately exercisable. The stock options are subject to time-based vesting conditions. 422 stock options are fully vested and immediately exercisable, and the remaining 141 stock options will vest on July 25, 2024, provided that the Reporting Person remains continuously employed by the Issuer on such date. The stock options are subject to time-based vesting conditions. 295 stock options are fully vested and immediately exercisable, 147 stock options will vest on July 25, 2024, and 148 stock options will vest on July 25, 2025, provided that the Reporting Person remains continuously employed by the Issuer on each such date. Exhibit 24.1 - Power of Attorney Jennifer Guckert Griffin, pursuant to a power of attorney 2023-09-05 EX-24 2 ex-24.htm ALLYSON GUIDROZ POWER OF ATTORNEY

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Jennifer Guckert Griffin the undersigned's true and lawful attorney-in-fact to:

1.    execute for and on behalf of the undersigned, in the undersigned's individual capacity, a Form ID, an Update Passphrase Confirmation, and Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the "Exchange Act");

2.    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute a Form ID and any Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

3.    take any and all other actions of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Amedisys, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on August 29, 2023.

/s/ Allyson Guidroz
Allyson Guidroz